4-Star Stocks Poised to Pop: Cubist Pharmaceuticals

Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biopharmaceutical company Cubist Pharmaceuticals (NAS: CBST) has earned a respected four-star ranking.

With that in mind, let's take a closer look at Cubist's business and see what CAPS investors are saying about the stock right now.

Cubist facts

Headquarters (Founded)

Lexington, Mass. (1992)

Market Cap

$2.24 billion



Trailing-12-Month Revenue

$663.2 million


CEO Michael Bonney
CFO David McGirr

Return on Capital (Average, Past 3 Years)



$1.01 billion / $444.9 million


Pfizer (NYS: PFE)
Teva Pharmaceutical (NAS: TEVA)

Sources: S&P Capital IQ and Motley Fool CAPS.

On CAPS, 95% of the 338 members who have rated Cubist believe the stock will outperform the S&P 500 going forward. These bulls include pchop123 and All-Star zzlangerhans, who is ranked in the top 0.5% of our community.

Late last month, pchop123 succinctly summed up the Cubist bull case: "[T]he price is right & I believe there is a good chance they will be acquired."

Over the next five years, in fact, Cubist is expected to grow its bottom line at a solid rate of 11.3% annually. That's faster than much larger drug stocks Pfizer (3.2%), Teva (8.5%), and Merck (NYS: MRK) (4.5%).

CAPS biotech expert zzlangerhans offers three good reasons to look into Cubist:

1. Growing revenues. Sequential quarterly numbers of 161M, 163M, and most recently 177M. Yes, all the revenues come from a single drug. But sales have been steadily growing for years and there's no generic until 2018. Cubicin was also recently approved in Japan which might give some juice to the top line.

2. Strong pipeline. Novel anti-pseudomonal cephalosporin CXA-201 has moved into phase III trials in UTI and will soon do the same with intra-abdominal infections. The company reported encouraging phase II data for c.diff antibiotic CB-183,215 in June but has not yet decided if and when to progress this candidate to a phase III trial.

3. Share price significantly off of recent highs. The share price was over 38 in June. There's only one thing bringing the stock down, and that's broad market uncertainty. When fund managers liquidate a speculative position because they can't remember what that ticker stood for, it's an opportunity for sector-focused traders to come in and pull the babies from the bathwater.

What do you think about Cubist, or any other stock for that matter? If you want to retire rich, you need to put together the best portfolio you can. Owning exceptional stocks is a surefire way to secure your financial future, and on Motley Fool CAPS, thousands of investors are working every day to find them. CAPS is 100% free, so get started!

Interested in another easy way to trackCubist?Add it to your watchlist.

At the time thisarticle was published Fool contributor Brian Pacampara owns no position in any of the companies mentioned. The Fool owns shares of Teva. Motley Fool newsletter services have recommended buying shares of Pfizer and Teva. Try any of our Foolish newsletter services free for 30 days.We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Fool's disclosure policy always gets a perfect score.

Copyright © 1995 - 2011 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.